In terms of its immunomodulatory activity on TAMs, there is preclinical evidence that heparanase may be responsible for this activity [10] and is known to direct the tumor-promoting behaviour of TAMs in pancreatic cancer [12], and promote disease progression in pancreatitis [13, 14] and pancreatic cancer [14–16]. Here, HPSE is linked to pancreatic neoplasm.